
News|Articles|October 3, 2026
Emerging Research Insights and New Advances in Neuroradiology
Author(s)Diagnostic Imaging Staff
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Advertisement
Advertisement
Will a new positron emission tomography (PET) agent be a game changer for glioma imaging? Are patients with diabetes and lower bone mineral density (BMD) on chest CT more susceptible to faster accumulation of white matter hyperintensity (WMH)? Can newly FDA-cleared software facilitate improved quality of amyloid PET imaging via structural MRI?
Related to this article

Catch up on the top radiology content of the past week.

In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),

Greater calcified plaque volume, quantified with AI assessment of carotid CTA, was associated with more than double the likelihood of obstructive coronary artery disease (OCAD), according to newly published research.

Uptunity | Aneurysm reportedly identifies suspected saccular brain aneurysms larger than 3 mm on head CTA and provides quantitative comparison between exams to assess changes in known aneurysms over time.

Through enhanced insights into atherosclerotic disease, complex coronary lesions and coronary stents, photon-counting CT provides an anatomical roadmap that may improve outcomes for interventional procedures.

In comparison to the RECIST 1.1 criteria, use of the mpMRI-based NacBI-RADS system for evaluating response to neoadjuvant chemotherapy (NAC) for breast cancer offered an 8 percent higher sensitivity and over 26 percent higher specificity.
Advertisement
Advertisement

